Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Shah

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
The Journal of Experimental Medicine|September 14, 2011
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemiaChristian Hurtz, Katerina Hatzi, Leandro Cerchietti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2021
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid LeukemiaCatherine C Smith, Aaron D Viny, Evan Massi, et al.
Leukemia|September 2, 2024
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Blood|December 2, 2006
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyAndreas Hochhaus, Hagop M Kantarjian, Michele Baccarani, et al.
JCI Insight|May 10, 2016
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A Minson, Catherine C Smith, Deborah DeRyckere, et al.
American Journal of Hematology|September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemiaHagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2012
Chronic myelogenous leukemiaSusan O'Brien, Camille N Abboud, Mojtaba Akhtari, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
The Journal of Experimental Medicine|September 14, 2011
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemiaChristian Hurtz, Katerina Hatzi, Leandro Cerchietti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2021
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid LeukemiaCatherine C Smith, Aaron D Viny, Evan Massi, et al.
Leukemia|September 2, 2024
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Blood|December 2, 2006
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyAndreas Hochhaus, Hagop M Kantarjian, Michele Baccarani, et al.
JCI Insight|May 10, 2016
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A Minson, Catherine C Smith, Deborah DeRyckere, et al.
American Journal of Hematology|September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemiaHagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2012
Chronic myelogenous leukemiaSusan O'Brien, Camille N Abboud, Mojtaba Akhtari, et al.
Pageof 12